QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Interim Chief Executive Officer. The main operative headquarters are located in Hilden, Germany.